September 15, 2020 -- Novus Therapeutics has completed the acquisition of Anelixis Therapeutics, including the lead clinical-stage compound AT-1501, a next-generation anti-CD40L antibody for the treatment of organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases.
Novus has also completed private placement funding of $108 million that will be used to fund operations including the advancement of AT-1501 to phase II clinical trials in renal transplantation, islet cell transplantation, autoimmune nephritis, and amyotrophic lateral sclerosis (ALS).
A previous phase I clinical safety study demonstrated that AT-1501 was well-tolerated at all doses tested in healthy volunteers and patients with ALS.
Copyright © 2020 scienceboard.net